MedTrace Logo

YF476 in Barrett's Esophagus

NCT02597712 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-04-12

Study results available
· View outcomes & findings →

Summary

A phase 2, randomised, double-blind, out-patient trial to determine if YF476 is a safe and effective treatment in patients with Barrett's esophagus.

Conditions

  • Barrett's Esophagus

Interventions

DRUG

YF476

gastrin receptor antagonist

DRUG

YF476 placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Julian A Abrams, MD MS · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-15
Primary Completion
2017-11-28
Completion
2017-12-27

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02597712 on ClinicalTrials.gov